Personalized Federated Learning for Predicting Disability Progression in Multiple Sclerosis Using Real-World Routine Clinical Data

dc.contributor.author Pirmani, Ashkan
dc.contributor.author De Brouwer, Edward
dc.contributor.author Arany, Adam
dc.contributor.author Oldenhof, Martijn
dc.contributor.author Passemiers, Antoine
dc.contributor.author Faes, Axel
dc.contributor.author Moreau, Yves
dc.date.accessioned 2025-08-25T16:58:32Z
dc.date.available 2025-08-25T16:58:32Z
dc.date.issued 2025
dc.description Taylor, Bruce/0000-0003-2807-0070 en_US
dc.description.abstract Early prediction of disability progression in multiple sclerosis (MS) remains challenging despite its critical importance for therapeutic decision-making. We present the first systematic evaluation of personalized federated learning (PFL) for 2-year MS disability progression prediction, leveraging multi-center real-world data from over 26,000 patients. While conventional federated learning (FL) enables privacy-aware collaborative modeling, it remains vulnerable to institutional data heterogeneity. PFL overcomes this challenge by adapting shared models to local data distributions without compromising privacy. We evaluated two personalization strategies: a novel AdaptiveDualBranchNet architecture with selective parameter sharing, and personalized fine-tuning of global models, benchmarked against centralized and client-specific approaches. Baseline FL underperformed relative to personalized methods, whereas personalization significantly improved performance, with personalized FedProx and FedAVG achieving ROC-AUC scores of 0.8398 +/- 0.0019 and 0.8384 +/- 0.0014, respectively. These findings establish personalization as critical for scalable, privacy-aware clinical prediction models and highlight its potential to inform earlier intervention strategies in MS and beyond. en_US
dc.description.sponsorship VLAIO PM: Augmenting Therapeutic Effectiveness through Novel Analytics [HBC.2019.2528]; Research Council KU Leuven [C14/22/125, C14/18/092, CELSA/21/019]; Flemish Government [S003422N, I002819N]; FWO-SB grant; Novartis; Biogen; Roche; FWO (Research Foundation Flanders); Fonds D.V. (Ligue Nationale Belge de la Sclerose en Plaques, Fondation Roi Baudouin); Charles University; Petre Foundation; Project National Institute for Neurological Research (Program EXCELES) - European Union-Next Generation EU [LX22NPO5107]; Brain Foundation; General University Hospital in Prague [MH CZ-DRO-VFN64165]; Royal Australasian College of Physicians; Biogen Idec; University of Sydney; Sanofi Genzyme; NHMRC Investigator Grant; Alexion; Almirall; Merck; Bristol; Novartis; Roche; FISM; Reload Association (Onlus); Italian Health Minister; University of Catania; Merck Serono; Teva; Czech Ministry of Education; Bristol Myers Squibb; Janssen; Sanofi-Genzyme; Sanofi/GenzymeOG; Viatris; Lundbeck; Genzyme; EMD Serono; Celgene; MS Australia; Trish MS Research Foundation; Bayer-Schering; Teva; Hikma; Teva Neurosciences; ATARA Pharmaceuticals; Sanofi Aventis; Merck Healthcare KGaA (Darmstadt, Germany); Bristol Meyer Squibb; Novartis Pharma; Neuraxpharm; Eisai; Swiss MS Society; Swiss National Research Foundation [320030\_189140/1]; University of Basel; Progressive MS Alliance; Alnylam; Immunic; Neurogenesis; Octave Bioscience; Quanterix; Sanofi; Stata DX; Sumaira Foundation; CSL; BMS; MedDay; NHMRC; Horizon/Amgen; National Health and Medical Research Council (NHMRC, Australia); [GNT2008339] en_US
dc.description.sponsorship A.Pirmani., Y.M. and M.O. are funded by (1) VLAIO PM: Augmenting Therapeutic Effectiveness through Novel Analytics (HBC.2019.2528); Research Council KU Leuven: Symbiosis 4 (C14/22/125), Symbiosis3 (C14/18/092; CELSA-Active Learning (CELSA/21/019). Y.M., M.O., and A.Pirmani. are affiliated to Leuven.AI and received funding from the Flemish Government (AI Research Program, FWO SBO (S003422N), and ELIXIR Belgium (I002819N)). E.D.B. and A.Passiemers. was funded by a FWO-SB grant. R.G. received honoraria as consultant on scientific advisory boards or as speaker from Biogen, Celgene-BMS, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Sandoz, Teva and Viatris. B.W. received consultancy and advisory board fees from Roche, Sanofi-Genzyme, Biogen, Merck-Serono, Bayer-Schering, Novartis and Allergan; received congress support from Biogen, Merck-Serono, Teva and Roche. She has also received research support from Novartis, Biogen, Roche, FWO (Research Foundation Flanders) and Fonds D.V. (Ligue Nationale Belge de la Sclerose en Plaques, Fondation Roi Baudouin). D.H .was supported by the Charles University: Cooperatio Program in Neuroscience, by the project National Institute for Neurological Research (Program EXCELES, ID Project No. LX22NPO5107)-Funded by the European Union-Next Generation EU, and by General University Hospital in Prague project MH CZ-DRO-VFN64165.She also received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva, as well as support for research activities from Biogen Idec. E.K.H. received travel and/or consultancy compensation from Sanofi-Genzyme, Roche, Teva, Merck, Novartis, Celgene, Biogen. F.P. received personal compensation for serving on advisory board by Almirall, Alexion, Biogen, Bristol, Janssen, Merck, Novartis and Roche. He further received research grant by Alexion, Almirall, Biogen, Bristol, Merck, Novartis and Roche and by FISM, Reload Association (Onlus), Italian Health Minister, and University of Catania.AL received speakers fees and travel grants from Novartis, Biogen, T'evalua, Sanofi. V.T. served on scientific advisory boards for Roche, Janssen, Sanofi-Genzyme, Novartis and Merck, received conference fee and travel support from Novartis, Biogen, Sanofi-Genzyme, Teva, Abbvie and Merck and received educational event support from Novartis. E.C. received honoraria/research support from Biogen, Merck Serono, Novartis, Roche, and Teva; has been member of advisory boards for Actelion, Biogen, Celgene, Merck Serono, Novars, and Sanofi Genzyme; received honoraria/research support from Biogen, Merck Serono, Novartiss, Roche, and Teva; has been member of advisory boards for Actelion, Biogen, Celgene, Merck Serono, Novartis, and Sanofi Genzyme; and has been supported by the Czech Ministry of Education-project Cooperatio LF1, research area Neuroscience, and the project National Institute for Neurological Research (Program EXCELES, ID project No LX22NPO5107)-funded by the European Union-Next Generation EU. I.R. received speaking/consulting fees and/or travel funding from Almirall, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. C.B. received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva. R.A. has received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Janssen, Bristol-Meyers, Bayer, Sanofi Genzyme, Roche and Teva. K.B. has no disclosures to declare. C.S. received personal compensation for consulting, serving on a scientific advisory board, speaking or other activities from Alexion, Amgen/Horizon, Biogen, Bristol Myers Squibb, Janssen/Johnson\&Johnson, Merck Serono, Novartis, Roche and Sanofi/Genzyme, and her institutions received research grants from Novartis, Roche and Sanofi/GenzymeOG has received consultation and speaker fees, travel grants and research support from: Biogen, Sanofi Genzyme, Merck, Novartis, Roche, Alexion, Viatris, Janssen, Bristol Myers Squibb, Almirall, Lundbeck. A.S. has served in advisory boards for Novartis, EMD Serono, Roche, Biogen idec, Sanofi Genzyme, Pendopharm and has received grant support from Genzyme and Roche, has received research grants for his institution from Biogen idec, Sanofi Genzyme, EMD Serono. J.K. has no disclosures. J.L.S.M. served on scientific advisory boards or as a consultant for MS International Federation and World Health Organisation, Therapeutic Goods Administration, BMS, Roche, Janssen, Genzyme, Novartis, Merck and Biogen, received conference travel support and/or speaker honoraria from WebMD Global, Merck, Sandoz, Novartis, Biogen, Roche, Eisai, Genzyme, Teva and BioCSL and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck. D.S. received speaking honoraria from Biogen, Novartis, Merck and Teva. T.C. served on scientific advisory boards, received conference travel support and/or speaker honoraria from Roche, Novartis, Merck and Biogen. I.R. is supported by MS Australia and the Trish MS Research Foundation. BVM received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis. R.A. received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme.VVPreceived honoraria as consultant on scientific advisory boards by Biogen, Bayer-Schering, Merck, Teva and Sanofi-Aventis; has received research grants by Biogen, Bayer-Schering, Merck, Teva and Novartis. N.J. received speaker honoraria and/or education support from Biogen, Teva, Novartis, Genzyme-Sanofi, Roche, Merck and Alexion; has been a member of advisory boards for Merck and Biogen. D.M. received honoraria and consulting fees from Bayer Schering, Novartis, Merck, Biogen and Genzyme. B.W.G. received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis. G.L. travel compensation from Novartis, Biogen, Roche and Merck. Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Biogen, Merck, Roche and Novartis. R.G. has received research grant and / or advisory board honoraria from Biogen, Hikma, Merck, Roche and Sanofi. A.A. accepted travel compensation from Novartis, Biogen, Genzyme, Teva, and speaking honoraria from Biogen, Novartis, Genzyme and Teva. A.A.A. has received a MENACTRIMS clinical fellowship grant (2020). A.V.D.W. received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, and ATARA Pharmaceuticals.Helmut Butzkueven served on scientific advisory boards for Merck, Genzyme, Almirall, and Biogen; received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva. B.T. received compensation for serving on IDMC for Biogen TAH has received travel grants from Merck Healthcare KGaA (Darmstadt, Germany), Biogen, Sanofi, Bristol Meyer Squibb, Almirall, Roche and Eisai. His institution has received research grants and consultancy fees from Roche, Biogen, Sanofi, Merck Healthcare KGaA (Darmstadt, Germany), Bristol Meyer Squibb, Janssen, Almirall, Novartis Pharma, Alexion, Neuraxpharm and Eisai. C.R. received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030\_189140/1), University of Basel, Progressive MS Alliance, Alnylam, Bayer, Biogen, Bristol Myers Squibb, Celgene, Immunic, Merck, Neurogenesis, Novartis, Octave Bioscience, Quanterix, Roche, Sanofi, Stata DX. O.G. accepted travel compensation from Novartis, Merck and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in clinical trials by Biogen, Merck and Roche. D.D. received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi-Aventis, Teva and Merck. A.G.K. received research funding, speaker honoraria and compensation for travel from and served as a consultant on advisory board for Bayer-Schering, Teva, Biogen, Merck, Genzyme and Novartis. M.F.P. has no relevant disclosure. M.S. received speaker honoraria/conference travel support from Biogen, Merck, Novartis, Roche, Sanofi-Aventis and Teva. N.S. has received honoraria as a speaker from Biogen, Merck, Novartis and Sanofi-Genzyme and for serving on scientific advisory boards from Novartis. B.S. Richard Macdonell or his institution have received remuneration for his speaking engagements, advisory board memberships, research and travel from Biogen, Merck, Genzyme, Bayer, Roche, Teva, Novartis, CSL, BMS, MedDay and NHMRC. M.C. NAJ is a PI on commercial MS studies sponsored by Novartis, Roche and Sanofi. He has received speaker's honoraria and consultancy fees from Merck. He has had conference travel and registration reimbursement; and consultancy fees from Novartis. PM received speaker honoraria for Advisory Board and travel grants from Alexion, Almirall, Bayer, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. P.L. received conference travel support from Novartis, Teva, Biogen, Bayer and Merck and has participated in a clinical trials by Biogen, Novartis, Teva and Actelion. C.A.S. served as a consultant for Biogen, EMD Serono, Novartis, Genentech, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, Bayer, Janssen, Labcorp, Horizon and SANA. Dr. Weinstock-Guttman also has received grant/research support from Novartis, Biogen, Horizon/Amgen. She serves in the editorial board for Children, CNS Drugs, MS International, Journal of Neurology Frontiers Epidemiology. S.H. has received research funding from the National Health and Medical Research Council (NHMRC, Australia), the Petre Foundation, the Brain Foundation, the Royal Australasian College of Physicians, and the University of Sydney. She is supported by an NHMRC Investigator Grant (GNT2008339). She serves as a consultant on the International Steering Committee for a clinical trial led by UCB (NCT05063162). She is on the advisory board for educational activities led by Limbic Neurology. She has been an invited speaker for educational/research sessions coordinated by Biogen, Alexion, Novartis, Excemed and Limbic Neurology. She is on the medical advisory board (non-remunerated positions) of The MOG Project and the Sumaira Foundation. en_US
dc.identifier.doi 10.1038/s41746-025-01788-8
dc.identifier.issn 2398-6352
dc.identifier.scopus 2-s2.0-105011413182
dc.identifier.uri https://doi.org/10.1038/s41746-025-01788-8
dc.identifier.uri https://hdl.handle.net/20.500.14365/6361
dc.language.iso en en_US
dc.publisher Nature Portfolio en_US
dc.relation.ispartof NPJ Digital Medicine en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.title Personalized Federated Learning for Predicting Disability Progression in Multiple Sclerosis Using Real-World Routine Clinical Data en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Taylor, Bruce/0000-0003-2807-0070
gdc.author.scopusid 57218114850
gdc.author.scopusid 57216982652
gdc.author.scopusid 54934398000
gdc.author.scopusid 57219510089
gdc.author.scopusid 57221527521
gdc.author.scopusid 57364216500
gdc.author.scopusid 36028311100
gdc.author.wosid Kermode, Allan/G-3568-2019
gdc.author.wosid Csepany, Tunde/M-1080-2019
gdc.author.wosid Alharbi, Talal/Aar-8260-2021
gdc.author.wosid Van Pesch, Vincent/Aak-9506-2020
gdc.author.wosid Sirbu, Carmen Adella/Aaa-9317-2020
gdc.author.wosid Roos, Izanne/Abo-3767-2022
gdc.author.wosid Çelik Soysal, Aysun/Abb-8478-2021
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp [Pirmani, Ashkan; De Brouwer, Edward; Arany, Adam; Oldenhof, Martijn; Passemiers, Antoine; Moreau, Yves] ESAT KU Leuven, STADIUS, Leuven, Belgium; [Pirmani, Ashkan; Faes, Axel; Peeters, Liesbet M.] Hasselt Univ, Biomed Res Inst, Hasselt, Belgium; [Pirmani, Ashkan; Faes, Axel; Peeters, Liesbet M.] Hasselt Univ, Data Sci Inst, Hasselt, Belgium; [Pirmani, Ashkan; Faes, Axel; Peeters, Liesbet M.] Univ Multiple Sclerosis Ctr, Hasselt, Belgium; [Kalincik, Tomas; Roos, Izanne] Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, Melbourne, Vic, Australia; [Ozakbas, Serkan] Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye; [Gouider, Riadh] Razi Univ Hosp, Clin Invest Ctr Neurosci & Mental Hlth, Dept Neurol, LR 18SP03, Tunis, Tunisia; [Willekens, Barbara] Antwerp Univ Hosp, Dept Neurol, Edegem, Belgium; [Willekens, Barbara] Univ Antwerp, Antwerp, Belgium; [Horakova, Dana; Havrdova, Eva Kubala] Charles Univ Prague, Gen Univ Hosp, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Patti, Francesco] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy; [Prat, Alexandre] Univ Montreal, CHUM, Montreal, PQ, Canada; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Tomassini, Valentina] Univ G Annunzio Chieti Pescara, Inst Adv Biomed Technol, Dept Neurosci Imaging & Clin Sci, Chieti, Pescara, Italy; [Grammond, Pierre] PRECA, Levis, PQ, Canada; [Cartechini, Elisabetta] AST Macerata, Diabetol & Metab Dis Unit, Macerata, Italy; [Boz, Cavit] Karadeniz Tech Univ, Fac Med, Dept Neurol, Trabzon, Turkiye; [Alroughani, Raed] Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait; [Amato, Maria Pia] Univ Florence, Dept NEUROFARBA, Florence, Italy; [Amato, Maria Pia] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy; [Buzzard, Katherine] Box Hill Hosp, Dept Neurosci, Box Hill, Vic, Australia; [Lechner-Scott, Jeannette] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia; [Guimaraes, Joana] Anatomopathol Dept, Unidade Local Saude Sao Joao, Porto, Portugal; [Guimaraes, Joana] Univ Porto, Dept Clin Neurosci & Mental Hlth, Fac Med, Porto, Portugal; [Solaro, Claudio] Galliera Hosp, Neurol Unit, Genoa, Italy; [Gerlach, Oliver] Zuyderland Med Ctr, Acad MS Ctr Zuyderland, Dept Neurol, Sittard Geleen, Netherlands; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkiye; [Kuhle, Jens] Univ Hosp Basel, Dept Neurol, Basel, Switzerland; [Sanchez-Menoyo, Jose Luis] Galdakao Usansolo Univ Hosp, Dept Psychiat, Osakidetza Basque Hlth Serv, Galdakao, Spain; [Spitaleri, Daniele] AORN San Giuseppe Moscati, UO Cardiol UTIC, Avellino, Italy; [Csepany, Tunde] Univ Debrecen, Fac Med, Debrecen, Hungary; [Van Wijmeersch, Bart] Univ MS Ctr, UMSC, Hasselt, Belgium; [Ampapa, Radek] Nemocnice Jihlava, Neurol Oddeleni, Jihlava, Czech Republic; [Prevost, Julie] CSSS St Jerome, St Jerome, PQ, Canada; [Khoury, Samia J.] Amer Univ Beirut, Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon; [Van Pesch, Vincent] Clin Univ St Luc, Dept Neurol, Brussels, Belgium; [John, Nevin] Monash Univ, Sch Clin Sci, Dept Med, Clayton, Vic, Australia; [Maimone, Davide] Azienda Osped Emergenza Cannizzaro, Ctr Sclerosi Multipla, UOC Neurol, Catania, Italy; [Weinstock-Guttman, Bianca] Jacobs MS Ctr Treatment & Res, Hackensack, NJ 07601 USA; [Laureys, Guy] Ghent Univ Hosp, Dept Neurol, B-9000 Ghent, Belgium; [Mccombe, Pamela] Royal Brisbane Hosp, Dept Neurol, Brisbane, Qld, Australia; [Blanco, Yolanda] Hosp Clin Barcelona, Ctr Neuroimmunol, Serv Neurol, Barcelona, Spain; [Altintas, Ayse] Koc Univ, Sch Med, Koc Univ Res Ctr Translat Med, Istanbul, Turkiye; [Al-Asmi, Abdullah] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Physiol, Muscat 123, Al Khodh, Oman; [Garber, Justin] Westmead Hosp, Dept Neurol, Sydney, NSW, Australia; [van der Walt, Anneke; Butzkueven, Helmut] Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia; [de Gans, Koen] Groene Hart Ziekenhuis, Gouda, Netherlands; [Rozsa, Csilla] Jahn Ferenc Teaching Hosp, Budapest, Hungary; [Taylor, Bruce] Royal Hobart Hosp, Hobart, Tas, Australia; [Al-Harbi, Talal] King Fahad Specialist Hosp, Pediat Neurol Dept, Dammam, Saudi Arabia; [Sas, Attila] BAZ Cty Hosp, Dept Pathol, Miskolc, Hungary; [Rajda, Cecilia] Univ Szeged, Dept Neurol, Szeged, Hungary; [Gray, Orla] South Eastern HSC Trust, Belfast, Antrim, North Ireland; [Decoo, Danny] AZ Alma, Sijsele Damme, Belgium; [Carroll, William M.] Univ Western Australia, Sir Charles Gairdner Hosp, Perron Inst Neurol & Translat Sci, Dept Neurol, Nedlands, Australia; [Kermode, Allan G.] QEII Med Ctr, Perron Inst, Nedlands, WA, Australia; [Fabis-Pedrini, Marzena] Univ Western Australia, Perron Inst Neurol & Translat Sci, Perth, WA, Australia; [Mason, Deborah] Christchurch Hosp, Christchurch, New Zealand; [Perez-Sempere, Angel] Hosp Gen Univ Alicante, Neumol, Alicante, Spain; [Simu, Mihaela] Univ Med & Pharm Victor Babes Timisoara, Timisoara, Romania; [Shuey, Neil] St Vincents Hosp Melbourne, Cardiol, Fitzroy, Vic, Australia; [Singhal, Bhim] Bombay Hosp & Med Res Ctr, Inst Med Sci, Dept Pediat, Mumbai, India; [Cauchi, Marija] Mater Dei Hosp, Dept Paediat, Birkirkara, Malta; [Hardy, Todd A.] Concord Repatriat Gen Hosp, Dept Neurol, Sydney, NSW, Australia; [Ramanathan, Sudarshini] Univ Sydney, Fac Med & Hlth, Kids Neurosci Ctr, Translat Neuroimmunol Grp, Sydney, Australia; [Lalive, Patrice] Geneva Univ Hosp, Fac Med, Dept Neurosci, Div Neurol, Geneva, Switzerland; [Sirbu, Carmen-Adella] Carol DavilaUnivers Med & Pharm, Dept Endocrinol, Bucharest, Romania; [Hughes, Stella] Royal Victoria Hosp, Dept Gastroenterol, Belfast, Antrim, North Ireland; [Castillo Trivino, Tamara] Hosp Univ Donostia IIS Biodonostia, Microbiol Dept, San Sebastian, Spain en_US
gdc.description.issue 1 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q1
gdc.description.volume 8 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q1
gdc.identifier.openalex W4412631047
gdc.identifier.pmid 40707601
gdc.identifier.wos WOS:001536298500003
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 4.0
gdc.oaire.influence 2.717486E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Science & Technology
gdc.oaire.keywords Health Care Sciences & Services
gdc.oaire.keywords CHALLENGES
gdc.oaire.keywords 4203 Health services and systems
gdc.oaire.keywords Human medicine
gdc.oaire.keywords Life Sciences & Biomedicine
gdc.oaire.keywords Medical Informatics
gdc.oaire.keywords Article
gdc.oaire.keywords STADIUS-25-140
gdc.oaire.keywords multiple sclerosis, progression, prognosis, indicators
gdc.oaire.popularity 5.78119E-9
gdc.oaire.publicfunded false
gdc.openalex.collaboration International
gdc.openalex.fwci 19.27898059
gdc.openalex.normalizedpercentile 0.98
gdc.openalex.toppercent TOP 10%
gdc.opencitations.count 0
gdc.plumx.mendeley 15
gdc.plumx.newscount 1
gdc.plumx.scopuscites 3
gdc.scopus.citedcount 3
gdc.wos.citedcount 3
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery e9e77e3e-bc94-40a7-9b24-b807b2cd0319

Files